Cambridge University Hospitals (CUH) cancer service stats
About 4,000 new cancer patients seen in Addenbrooke’s each year. Referrals and most treatment activity rising at between 5% and 10% per year.
- Survival rates are better than the national average
- CUH is the first general hospital in Europe to be accredited as a Comprehensive Cancer Centre by the Organisation of European Cancer Institutes
- 90% of all prostate operations are carried out using minimally invasive robotic surgery at Cambridge compared to a national average of 20%.
- The national agenda is to improve access to Intensity Modulated Radiation Treatment (IMRT). This reduces the toxic side-effects of radiotherapy and enables higher radiation doses to be given. Addenbrooke’s treats 30% of patients with IMRT, compared to the national average of 13%.
- Addenbrooke’s treats more than 90% of patients as day cases; one of the highest rates in the UK
- There are more than 80 NHS consultants of all disciplines working on cancer (including radiology and pathology)
Clinical Research at Addenbrooke’s
- More than 50% of new patients were enrolled in randomised control trials in 2012/13 in the cancer network (the highest rate in England)
- 250 current cancer trials in Cambridge, of which 160 are open to new recruitment
- West Anglia Cancer Research Network enrolled more than 7,000 patients to clinical trials (including screening studies) in 2012/13, the 2nd highest figure in England
- Recent completed trials led from Cambridge have changed UK practice in: breast cancer prognosis and treatment prediction; breast precision radiotherapy; molecular diagnosis of myeloproliferative neoplasms; and standard chemotherapy regimens for oesophageal and stomach cancers, and advanced pancreatic neuro-endocrine tumours.
Cancer Science in and around Cambridge
- Over the past 15 years, three major laboratories in Cambridge have been created with a focus on cancer research: the Cancer Research UK Cambridge Institute/Li Ka Shing Centre; the Hutchison/Medical Research Council Research Centre; and significant cancer focused work undertaken in the Strangeways Research Laboratory. Today these laboratories provide workspace for almost 500 researchers, plus state-of-the-art supporting facilities for technologies such as genome sequencing, molecular imaging, microscopy and computational biology
- Cancer is one of the 8 Strategic Initiatives of the University of Cambridge
- Grant income into the University on Cancer = £65 million/ year (this excludes MRC LMB and Sanger Institute)
- Within a few miles of the Campus are other leading laboratories with strong cancer research interests such as the Wellcome Trust Sanger Institute, the Gurdon Institute and the Babraham Institute
- In 2016, this cancer research and innovation ‘cluster’ will be strengthened further when AstraZeneca opens a new global cancer-focused research centre on site
- In 2013, the contribution of Cambridge was recognised through its accreditation as a Comprehensive Cancer Centre by the Organisation of European Cancer Institutes (OECI); one of only six centres in Europe and two in the United Kingdom to be recognised in this way, and the first in a general hospital
- Around 150 cancer research groups exist throughout Cambridge are part of the Cambridge Cancer Centre
- More than 2,400 cancer research papers were published in the last 40 months; 177 of these were in high impact international journals (impact factor >20) – i.e. more than 1 a week.
- It is predicted that, by 2020, almost half of Britons will get cancer in their lifetime.
- Over 250,000 people in England are diagnosed with cancer every year and around 130,000 die from the disease. Currently, about 1.8m people are living with, and beyond, a cancer diagnosis.